The lineup includes low-dose CagriSema results from REDEFINE 9, real-world Wegovy pill data, and full STEP Young results in children ages 6 to under 12.
Recap by typeshit. Full story at Yahoo Finance.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Health and Me ties the Australian actor and stuntman's death to peptides as RFK Jr. moves to loosen US rules on six unapproved peptides over FDA objections.
3:34
ABC News Australia reports on pressure on the regulator to tighten rules on peptides that haven't been approved.
Loading…